Free Newsletter
NIAID finds antibodies that neutralize H5N1
Federal scientists at the NIAID have developed a vaccine that protects mice against the killer 1918 influenza virus. But they have also created a technique for identifying antibodies that neutralize the bird flu virus, a tool that could help contain future pandemic flu strains. These findings are important, the researchers say, to understanding and preventing the recurrence of the H1N1 influenza virus that caused the 1918 pandemic and to protecting against virulent flu strains in the future, including the H5N1 avian flu virus.
"Who would have imagined five years ago that we'd be able to create a vaccine that protects against one of the deadliest forms of influenza the world has ever seen?" said Gary J. Nabel, M.D., Ph.D., director of the Vaccine Research Center. "It's because the 1918 flu virus has been reconstructed that we are now able the further understand it. Hopefully, this virus will help us to develop effective vaccine strategies for current pandemic influenza virus threats."
- see the release from PressZoom
ALSO: Up to now it was not known how cells distinguish their own RNA from that of 'enemy' viruses. An international team of researchers have shown that the instructions from the cell's nucleus carry a kind of 'signature', which is missing in the virus commands. Release
Related Article:
At the 2006 Mid-Atlantic Bio conference, Dr. Tony Fauci, director of NIAID, delivered a fascinating speech on emerging and re-emerging infectious diseases such as the bird flu. Article
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: